A Novel In Vivo siRNA Delivery System Specifically Targeting Liver Cells for Protection of ConA-Induced Fulminant Hepatitis

Nan Jiang1,2,3*, Xusheng Zhang1,2*, Xiufen Zheng1,2, Di Chen1,2, Kingsun Siu1,2, Hongmei Wang4, Thomas E. Ichim5, Douglas Quan1,2, Vivian McAlister1,2, Guihua Chen3, Wei-Ping Min1,2,4**

1 Multi-Organ Transplant Program, London Health Sciences Centre, London, Ontario, Canada, 2 Department of Surgery, Pathology, and Oncology, University of Western Ontario, London, Ontario, Canada, 3 Liver Transplant Center, The Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou, China, 4 Jiangxi Provincial Institute of Medical Science, and Medical School of Nanchang University, Nanchang, China, 5 Medistem Laboratories, San Diego, USA

Abstract

Background: Fulminant hepatitis progresses to acute liver failure (ALF) when the extent of hepatocyte death exceeds the liver’s regenerative capacity. Although small interfering RNA (siRNA) appears promising in animal models of hepatitis, the approach is limited by drawbacks associated with systemic administration of siRNA. The aim of this study is to develop a hepatocyte-specific delivery system of siRNA for treatment of fulminant hepatitis.

Methodology/Principal Findings: Galactose-conjugated liposome nano-particles (Gal-LipoNP) bearing siRNA was prepared, and the particle size and zeta potential of Gal-LipoNP/siRNA complexes were measured. The distribution, cytotoxicity and gene silence efficiency were studied in vivo in a concanavalin A (ConA)-induced hepatitis model. C57BL/6 mice were treated with Gal-LipoNP Fas siRNA by i.v. injection 72 h before ConA challenge, and hepatocyte injury was evaluated using serum alanine transferase (ALT) and aspartate transaminase (AST) levels, as well as liver histopathology and TUNEL-positive hepatocytes. The galactose-ligated liposomes were capable of encapsulating ~96% siRNA and exhibited a higher stability than naked siRNA in plasma. Hepatocyte-specific targeting was confirmed by in vivo delivery experiment, in which the majority of Gal-LipoNP-siRNA evaded nuclease digestion and accumulated in the liver as soon as 6 h after administration. In vivo gene silencing was significant in the liver after treatment of Gal-Lipo-siRNA. In the ConA-induced hepatitis model, serum levels of ALT and AST were significantly reduced in mice treated with Gal-LipoNP-siRNA as compared with control mice. Additionally, tissue histopathology and apoptosis showed an overall reduction of injury in the Gal-LipoNP siRNA-treated mice.

Conclusions/Significance: This study is the first to our knowledge to demonstrate reduction of hepatic injury by liver-specific induction of RNA interference using Gal-LipoNP Fas siRNA, highlighting a novel RNAi-based therapeutic potential in many liver diseases.

Introduction

Fulminant hepatitis is a devastating liver disease caused by autoimmune hepatitis, alcohol consumption, chronic or acute viral hepatitis infection, which remains a significant cause of morbidity and mortality internationally [1,2]. Fulminant hepatitis is associated with severe hyperbilirubinemia, hepatic encephalopathy and death. However, the underlying pathogenesis mechanisms are not fully elucidated. Therefore, a therapeutic approach is difficult and stringent need new accepted therapy that will ameliorate or prevent fulminant hepatitis.

Induction of RNA interference (RNAi) using short interfering RNA (siRNA) promises superior advantages to other drug-development approaches given easy of design, high target selectivity, and expected low toxicity due to metabolism to natural nucleotide components by the endogenous cell systems [3–7].
However, siRNA therapeutics is hindered by the poor intracellular uptake and limited blood stability of siRNA which limits effective delivery of the therapeutic molecules to their targets. When siRNA is administered intravenously, it is readily digested by nucleases and largely cleared from the kidney glomeruli before reaching the diseased organs. In order to facilitate site-specific delivery and achieve the therapeutic effect, it is important to increase the stability of siRNA duplexes in the blood circulation and enable the targeted delivery directly to the diseased area.

In vivo delivery techniques that have been applied to siRNA have historically included viral vectors [8], hydrodynamic injection [9] and cationic liposomes [10]. However, viral vector-based siRNA delivery overcomes the problem of poor transfection, clinical application of this approach is beset by concerns about potential adverse effects such as onco genesis [11–13]. Previous studies have showed that hydrodynamic injection of naked siRNA is effective in reducing the expression of Caspase 8 [14] or Fas [9] in mouse fulminant hepatitis model and reduces corresponding liver injury. Although this method can reach the desired gene silencing effect, drawbacks exist such as non-selective delivery of the nucleotides, and clinical impracticality due to need for large volume and high injection speed [15]. In recent years, cationic liposomes emerged as the most promising delivery system due to ability to protect from circulating nucleases and escape from intracellular endosomal degradation [16–18]. In this study, we report a novel liver-specific targeting method for siRNA delivery; the use of the galactose-guided liposomal-based siRNA delivery system is efficient for silencing Fas, a critical mediator of hepatocyte death. We demonstrate effective gene silencing through local delivery of the siRNA, and prevention of hepatic injury using this selective delivery system.

Materials and Methods

Chemicals

1,3-Dioleoyl-3-trimethylammonium propane (DOTAP), cholesterol, 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC), 1,2-distearyloyleoyl-sn-glycero-3-phosphoethanolamine-N[carboxy(polyethylene glycol)-2000] (DSPE-PEG2000-Carboxylic Acid) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Avanti Lipids, Inc. (Alabaster, AL). 4-Aminophenyl-D-galactopyranoside (0.24 mmol) and pyridine (2 ml) incubated at room temperature for 10 min, the mixture was supplemented with an excess amount of 4-Aminophenyl D-galactopyranoside and pyridine (2 ml) incubated at room temperature overnight. Pyridine was removed by rotary evaporation. After the reaction mixture was evaporated in vacuo, the resultant material was suspended in water, and dialyzed against distilled water for 48 h using a 3 kDa cut-off membrane (Spectrum, USA). After the dialysis, the products were centrifuged, filtered with Amicon Ultra-15 centrifugal filter units (Millipore; MWCO 3KDa) and freeze-dried.

Preparation of siRNA

A total of 50 μg Cy3-labeled Fas siRNAs were mixed with full-length recombinant protamine in a 1:5 (siRNA:protamine) molar ratio, in DNA RNAase nuclease-free water (Gibco-InVitrogen) and were pre-incubated for 20 min at room temperature to form a complex.

siRNA-liposome preparation

Multilamellar liposomes, composed of 1,2-Dioleoyl-3-Trimethylammonium -Propane (DOTAP), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and cholesterol(Chol) (Avanti Polar Lipids, Alabaster, AL, USA) at molar ratios of 2:7:7 (DOTAP/DPPC/Chol) were prepared by a thin lipid film method. Briefly, the lipids were dissolved in chloroform in a glass tube and gently dried under nitrogen and further evaporated to dryness under vacuum. The lipid film was hydrated with a swelling solution composed of protamine and the condensed siRNA (5 mmol) was dissolved in RNAase nuclease-free water to create unilamellar liposomes. The resulting multilamellar liposomes suspension was exposed to 5 freeze/thaw cycles by alternately placing the sample vial in a dry ice bath and warm water bath. The dispersion was then vortexed for 5 min and sonicated for 2 min using a bath sonicator above the Tc(50°C) of the lipid and then subjected to extrusion (Avanti Polar Lipids, USA) through polycarbonate membranes (Avanti Polar Lipids, USA) with gradually decreasing pore size (0.4, 0.2 and 0.1 μm) to produce unilamellar nanoparticles (NP) with 30 cycles each at 50°C. Targeting liposome (Gal-LipoNP) and non-targeting liposome (LipoNP) were generated by incubating the mixture of unilamellar nanoscale liposome suspension with 10 mol% micelle solution of Gal-DSPE-PEG2000, DSPE-PEG2000, respectively, at 50°C for 10 min, and then cooled down at room temperature.

Particle diameter and zeta potential measured

The Non-targeting and targeting liposome were freshly prepared and diluted with phosphate-buffered saline (PBS), and the mean particle diameter and surface charge (zeta potential) measured by dynamic light scattering and Malvern Zetasizer nano ZS (Malvern Instruments Ltd., Worcestershire, UK), according to the manufacturers’ protocols.

Efficiency of siRNA entrapment inside liposomes

The siRNA entrapment efficiencies were determined using Cy3-labeled siRNAs. Samples were diluted in nuclease free water to the concentration that falls within the linear range of the standard curve. The sample concentrations were then calculated according to standard curve. The intensity of siRNA encapsulated within liposomes was measured fluorescence intensities in the presence or absence of Triton X-100 at wavelengths of excitation...
Protection of siRNA by liposomes in mouse plasma

To assess the stability of liposomes-siRNA complex in blood plasma in vitro, 30 μL siRNA (2 μg) was incubated with 270 μL fresh mouse plasma at 37°C for various time periods. The siRNA were either naked or encapsulated by PEGylated liposome. The siRNA inside liposomes were extracted by 0.1% Triton X-100 solution. The reaction was terminated with 10% sodium dodecyl sulfate solution. The degradation of liposome-siRNA complex was determined by 12% polyacrylamide gel electrophoresis followed by visualization by a Fluor-S Multi-Mager (Bio-Rad).

In vivo biodistribution of liposomes/siRNA complex

Cy3-labeled siRNA (50 μg) was encapsulated by Gal-LipoNP and LipoNP. Mice were treated with liposomes/siRNA complex via tail vein. Other control groups included injection of same amount of naked Cy3-labeled siRNA and naive group. At 6 h, 24 h and 48 h following administration, the organs including heart, liver, spleen, lung and kidney were harvested and rinsed with saline, frozen in liquid nitrogen and mounted for cryostat sectioning. Slides were viewed under a fluorescence microscope.

Fluorescence intensity and gene silencing efficiency

Different doses of Fas-siRNA (0.125 nmol/g–0.75 nmol/g) were encapsulated by Gal-LipoNP. Mice were treated with liposomes/siRNA complex via tail vein injection. 6 h later, livers were harvested and rinsed with saline, frozen in liquid nitrogen and mounted for cryostat sectioning. Slides were viewed under a fluorescence microscope. As a parallel experiment, another group of mice were exposed to the same treatment. 72 h later, the expression of Fas gene in liver was detected by quantitative PCR.

Detection of non-specific inflammation in liver

Three groups of mice were injected with Gal-LipoNP/Fas siRNA (0.25 nmol/g) complex, Gal-LipoNP/Gl2 siRNA (0.25 nmol/g) complex and PBS via tail vein respectively. 4 h later, the livers were excised and total RNA was extracted, expression levels of IFN-γ, TNF-α and IL-6 mRNA were detected by real-time PCR.

Fulminant hepatitis model and siRNA treatment

ConA (Sigma) was dissolved in pyrogen-free PBS at a concentration of 1 mg/ml and injected intravenously through the tail vein (15 mg/kg) [21]. To investigate the efficacy of protection on fulminant hepatitis injury by siRNA, the mice were administered with siRNA 72 h before ConA injection. 0.25 nmol/g of Fas siRNA were encapsulated by Gal-LipoNP and LipoNP, then diluted in 300 μl of PBS and injected into mice at a normal pressure by tail vein. Hydrodynamic administration was performed by intravenous injection of naked siRNA in a volume of 1.6 ml. Control groups included Gal-LipoNP/Gl2 siRNA and PBS-treated mice.

Assessment of liver function

Blood samples were obtained from the inferior vena cava at 24 h after ConA injection. Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured by the core laboratory at the London Health Sciences Center to monitor liver function.

Liver histology and apoptosis

At 24 h post-ConA injection, livers were dissected from mice and tissue slices were fixed in 10% formalin and processed for histology examination using standard techniques. Formalin tissue was embedded in paraffin and 5 μm sections were stained with H&E. Ten random fields were assessed for necrosis by standard morphologic criteria. These sections were examined in a blinded fashion by a pathologist. For analysis of apoptosis, TUNEL assay was performed. Liver tissue sections were stained with the in situ cell-death detection kit (Roche) following the manufacturer’s instructions. TUNEL-positive cells were determined by observing 1000 cells in randomly selected fields [22].

Quantitative PCR

Total RNA was extracted from livers using Trizol (Invitrogen). RNA was reverse-transcribed using oligo-(dT) primer and reverse transcriptase (Invitrogen). Quantitative PCR reactions were performed to examine gene expression in Stratagene MX 4000 multiplex quantitative QPCR system using SYBR Green PCR Master mix (Stratagene, La Jolla, CA, USA) and 100 nM of gene-specific forward and reverse primers. Primers used for the amplification of murine Fas, TNF-α, IFN-γ, IL-6 and GAPDH were as follows: Fas, 5'-AAGGGAAGGAGTACATGGACAAGA-3' (forward) and 5'-GTATGTGTTTTCAAGCAGATGGTTC -3'(reverse); TNF-α, 5'-CCATCTCCCTGAGACAGAC-3'(forward) and 5'-AGCCGAGACCCATGGAAAGA-3'(reverse); IFN-γ, 5'-CCATCGCGTGCACCTAGAGAAAGACAAT-3'(forward) and 5'-AGGCCGAGACCCATGGAAAGA-3'(forward); IL-6, 5'-CAACCCAGGCGTCTCCCTGCTCTACT-3'(forward) and 5'-TCATTTCGCGATTTCCAGGAG-3'(reverse) and GAPDH, 5'-GATGACCTCAAGAAGGTTGGA-3'(forward) and 5'-TGGGATGGAATTTGAGGAGAT-3'(reverse). The reaction conditions were 10 min at 95°C, 15 s at 95°C, 1 min at 58°C and 1 min at 72°C (40 cycles). Samples were normalized using the housekeeping gene GAPDH, and a comparative CT method was used for the analysis.

Western Blot

Liver tissue samples were lysed in ice-cold RIPA buffer (Cell Signaling Technology, Danvers MA) supplemented with 1 mM phenylmethanesulfonylfluoride (PMSF, Sigma) on ice for 15 min. Insoluble material was removed by subsequent centrifugation at 14,000 rpm for 10 min at 4°C. Protein concentrations were determined by the Bradford assay (Bio-Rad, Hercules, CA). Fifty micrograms of protein was size-fractionated using SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked by 5% non-fat milk containing 1X Tris-buffered saline and 0.1% Tween 20 (TBST) for 1 h at room temperature, and then incubated with specific antibodies specific for Fas and β-actin (Santa Cruz, CA, USA) at 4°C overnight.

Statistical analysis

All results are presented as means ± SD. Statistical comparisons between groups were performed using Student’s t-test. Statistical significance was determined as p<0.05.
Results

Formulation and characterization of Gal-LipoNP

In this study, Fas siRNA was encapsulated within the aqueous interior of Lipo-NP that were conjugated to the galactose, a ligand that specifically binds the hepatocyte-specific asialoglycoprotein receptor (ASGP-R) [23]. Gal-LipoNP were prepared by first mixing Cy3-labeled Fas siRNA and protamine with liposomes composed of the neutral lipid cholesterol, DPPC and cationic lipid DOTAP to form liposomes through the freeze/thawing technique. Subsequently, liposomes were repeatedly extruded through polycarbonate filter membranes with pore sizes of 400, 200, 100 nm to produce a liposome population of uniform size. Subsequently, the post insert technique [24] was used to allow galactose lipids modify surface of the cationic liposomes complex to construct liposome-based targeted NPs for siRNA delivery.

The physicochemical characteristics of the liposome/siRNA complex are summarized in Table 1. The particle diameters of targeting liposome (Gal-LipoNP) and non-targeting liposome (LipoNP) were similar [115.9±0.46 nm vs 120.2±0.87 nm], whereas without DSPE-PEG lipid modified siRNA liposome were 10–15 nm smaller than both of them. The potential zeta was reduced by DSPE-PEG surface modification [14.17±1.38 mV and 12.67±1.58 mV] compared with those of naked siRNA liposome [24.23±0.67 mV], suggesting that electrostatic interaction between PEG, liposomes and siRNA controlled the size and magnitude of the zeta potential.

Stability of liposome/siRNA complex in mouse plasma

To determine the stability of the liposome/siRNA complex, liposome/siRNA complex and naked siRNA were exposed to mouse plasma that is known to contain numerous RNA-degrading activities, such as various RNases. Naked siRNA degradation was observed after 30 min of incubation with plasma and almost more than 90% digestion by nucleases was observed within 6 h. In contrast, liposome/siRNA complex displayed significant stability under the same conditions with no significant degradation detected at the 48 h (Figure 1). Taken together, these data suggest that the liposome exerts a protective effect on the siRNA, thus supporting in vivo application.

Distribution of Gal-LipoNP in vivo

In order to test whether Gal-LipoNP can specifically target hepatic tissue, we investigated the biodistribution of siRNA in vivo at 6 h, 24 h, 48 h after administration of the galactosylated liposomes/Cy3-labeled siRNA complex. Figure 2 shows images of frozen sections of different organs at the 6 h time points under fluorescence microscopy. In the Gal-LipoNP/siRNA complex injected mice, Cy3 labeled siRNA was detected abundantly in liver and the fluorescence intensity was higher than that in the mice injected with LipoNP/siRNA complex. In contrast, animals treated with control LipoNP/siRNA displayed significant accumulation in the spleen and only small amounts of siRNA in liver cells. Most of naked siRNA was eliminated from the blood and excreted from kidney. Additionally, Gal-LipoNP prolonged the circulation of siRNA in the mouse bloodstream compared with naked siRNA; the fluorescence was still detectable in the liver 24 h and 48 h after injection of Gal-LipoNP/siRNA complex. These data suggest the possibility that Gal-LipoNP/siRNA slowly distributed in organs instead of eliminated in short time.

Fas expression can be silenced by Gal-LipoNP in vivo

Upon confirmation that siRNA can be delivered to liver tissue through systemic administration of galactosylated liposome, we next investigated the ability of the siRNA suppresses endogenous gene expression in liver. In this study, we chose Fas as a sample target gene, given that recent evidence has implicated Fas highly expressed on hepatocytes and causes hepatic injury through Fas-mediated apoptosis [25,26]. We first tested the gene silence efficiency in different doses. Mice were treated with different dose Fas-siRNA encapsulated by Gal-LipoNP (0.125 nmol/g–0.75 nmol/g) via tail vein. 72 h later, the expression of Fas gene was detected by real-time PCR and western blot (Figure 3A and 3B). We found that Gal-LipoNP/Fas-siRNA complex induces silencing rate and the fluorescence intensity have dose-dependent manner. When 0.125 nmol/g siRNA was administrated to mice, only about 13% gene silencing effect was observed; 0.19 nmol/g siRNA was administrated to mice, about 50% gene silencing effect was observed. When increase siRNA dose from 0.25 nmol/g to 0.75 nmol/g, gene silencing effect can reach above 90%, however, suppression of Fas gene expression was not different between them (Figure 3A and 3B). Figure 3C shows the fluorescence intensity increase with the siRNA dose from 0.25 nmol/g to 0.75 nmol/g. The results indicate that the effective range of siRNA dose-dependence is from 0.25 to 0.75 nmol/g when Gal-LipoNP is used. Based on these results, we choose 0.25 nmol/g as treatment dose in later experiments.

We subsequently investigated the time course of gene-inhibition achieved by Gal-LipoNP. Mice were treated with Gal-LipoNP/Fas siRNA (0.25 nmol/g) complex via tail vein and subsequently sacrificed mice daily from day 1 to day 7 to assays Fas gene expression by quantitative PCR and western blot. We found that Gal-LipoNP/Fas siRNA complex induces silencing efficiency reach peak at the third day and then gradually attenuated, but at the seventh day, 50% gene silencing effect was observed (Figure 3D and 3E). Based on these results, we choose administered Gal-LipoNP/Fas siRNA complex three days before ConA-induced fulminant hepatitis.

Gal-LipoNP/siRNA complex does not induces non-specific inflammatory responses in liver

Previous siRNA approaches have been associated with non-specific inflammatory responses [27], which hinders therapeutic development. To determine whether such responses may occur using our new approach, we assessed hepatic levels of IFN-γ, TNF-α as well as IL-6 using real-time PCR at 4 h following

Table 1. Particle size, zeta potential and envelopment efficiency of liposomes/siRNA complex.

| Formulations                      | Particle size (nm) | Potential (mV) | Envelopment efficiency (%) |
|-----------------------------------|--------------------|----------------|---------------------------|
| Liposomes/Fas siRNA               | 106.3±1.11         | 24.23±0.67     | 96.7±1.4                  |
| DSPE-PEG Liposomes/Fas siRNA      | 120.2±0.87         | 12.67±1.58     | 94.9±1.1                  |
| Gal-DSPE-PEG Liposomes/Fas siRNA  | 115.9±0.46         | 14.17±1.38     | 95.2±1.9                  |

doi:10.1371/journal.pone.0044138.t001
administration Gal-LipoNP/siRNA complex. As shown in Figure 4A, the level of these inflammatory cytokines induced by Gal-LipoNP/Fas siRNA and control Gal-LipoNP/Gl2 siRNA were not higher than that in PBS controls. The Gal-LipoNP/siRNA complex did not increase ALT and AST levels in mouse serum compared with the levels in PBS treated mice (Figure 4B). These results indicate that administration of Gal-LipoNP/siRNA complex do not induced non-specific inflammatory responses and hepatocyte injury.

Gal-LipoNP/siRNA complex attenuates ConA-induced liver dysfunction

We used ConA induced fulminant hepatitis model to compare expression of Fas mRNA in different treatment groups. The siRNA treatments were performed 72 h before ConA challenge. We administered 0.25 nmol/g Fas-siRNA encapsulated by Gal-LipoNP and LipoNP via tail vein treated mice. The gene suppression effects were also compared with those following hydrodynamic injection of naked Fas-siRNA. Other controls included use scrambled sequence Gl2 siRNA were encapsulated by Gal-LipoNP and PBS groups. The silencing effect of the Fas

Figure 1. Stability of galactosylated liposomes/siRNA complex in mouse plasma. Cy3-labeled siRNA was complexed with galactosylated liposomes or naked siRNA and was subsequently incubated with fresh mouse plasma at 37 °C for various time periods. After incubation for 0, 1, 3, 6, 12, 24, and 48 h, siRNA from galactosylated liposomes was extracted with Triton X-100 and detected by polyacrylamide gel electrophoresis.

doi:10.1371/journal.pone.0044138.g001

Figure 2. Distribution of liposomes/siRNA complex in vivo. C57BL/6 mice were i.v. injected with naked Cy3-labeled siRNA (Naked siRNA), non-targeted liposomes (lipoNP/siRNA) and targeted liposomes with Cy3-labeled siRNA complex (Gal-LioNP/siRNA). Untreated mice served as naïve control. At 6 h, 24 h and 48 h following administration, mice were sacrificed and heart, liver, spleen, lung, kidney were collected. The remaining siRNAs in organs were detected by fluorescence microscope.

doi:10.1371/journal.pone.0044138.g002
Figure 3. Silencing Fas in vivo. **(A&B) Effect of siRNA dose on gene silencing in mice.** Gal-liposomes/Fas-siRNA complex was i.v. injected into C57BL/6 mice (n = 6, per group) at a siRNA dose from 0.125 nmol/g to 0.75 nmol/g. GL2 siRNA and PBS treatments were used as negative controls. Gene silencing of Fas in liver was determined using quantitative RT-PCR (A) and western blot (B).

**(C) fluorescence intensity.** Mice were treated with Cy3-labeled Gal-liposomes/Fas-siRNA complex as described in (A). The liver tissues were sectioned and the fluorescence was detected under microscope as described in Materials and Methods.

**(D&E) Dynamic observation of gene silencing.** Gal-liposomes/Fas-siRNA complex was i.v.
gene expression in liver was observed with each complex after Fas-siRNA administration. The Gal-LipoNP/Fas siRNA group exhibited greater suppression of Fas gene expression compared with LipoNP/Fas siRNA, as well as the Gal-LipoNP/Gl2 siRNA and naked Fas siRNA treated groups. The gene silencing efficiency only less than 20% in hydrodynamic injection delivery naked Fas siRNA group (Figure 5A). These results show that the Gal-LipoNP exhibited effective means as a hepatic targeting delivery system for siRNA gene silencing in vivo.

Given that siRNA appeared to block the expression of Fas, we hypothesized that siRNA also would prevent liver injury caused by Fas mediated hepatic injury. Accordingly, we measured ALT and AST levels 24 h after ConA injection, to assess the degree of liver dysfunction, the levels of both ALT and AST in Gal-LipoNP Gl2 siRNA, naked Fas siRNA and LipoNP Fas siRNA treated group significantly increased when compared with PBS group. However, treatment with Gal-LipoNP/siRNA complex, prior to inducing hepatitis, significantly prevented increase of ALT and AST values 24 h after hepatocyte injury (Figure 5B).

**Gal-LipoNP/siRNA complex prevents ConA-induced inflammatory response and apoptosis**

Histopathology changes and apoptotic hepatocytes of hepatitis injury, as an additional indicator of tissue injury were subsequently examined as an additional measure of protection from ConA-
Figure 5. Protecting ConA-induced hepatic injury using Gal-LipoNP/Fas siRNA. C57BL/6 mice were treated with Gal-LipoNP containing Fas siRNA or GL2 siRNA, LipoNP that incorporated with Fas siRNA, Other control groups included naked siRNA administration by hydrodynamic injection and PBS group. 72 h after gene silencing, mice were administered (15 mg/kg) ConA intravenously. After 24 h injury, liver tissues were collected and total RNAs were extracted. Fas Gene suppression (A) and ALT and AST levels (B) were measured. The livers were stained with H&E (C). The apoptotic cells in the liver tissues were detected using TUNEL assay (D), and the percentage of apoptotic cells were counted (E). (a) C57BL/6 mice treated with PBS; (b) Gal-LipoNP containing GL2 siRNA; (c) naked Fas siRNA administration by hydrodynamic injection; (d) LipoNP containing Fas siRNA; (e) Gal-LipoNP containing Fas siRNA. Values are given as mean ± SD (n = 6, per group). (*) Statistical significance when compared with Gal-LipoNP/Fas siRNA and Gal-LipoNP/GL2 siRNA groups was denoted at p < 0.05.

doi:10.1371/journal.pone.0044138.g005
induced pathology. As seen in Figures 5, control groups (Gal-LipoNP/G2 siRNA, naked Fas siRNA and LipoNP/Fas siRNA treated mice) showed evident edema, hepatocellular necrosis, neutrophil invasion (Figure 5C) and high numbers of TUNEL-positive hepatocytes (Figure 5D and 5E). In contrast, mice pretreated with Gal-LipoNP/Fas-siRNA demonstrated significant attenuation of all pathological changes and marked reduction in cell apoptosis.

**Discussion**

Chronic or acute hepatitis B and C virus infection often progresses towards fulminant hepatitis, which is associated with high level of morbidity and mortality, which represents a major unmet medical need. Given the known role of Fas in triggering hepatocyte death, we developed a tissue and gene-specific silencing approach using targeted nanoparticles bearing siRNA, which was capable of successfully targeting hepatocytes, inducing gene silencing, and inhibiting pathological changes associated with the hepatotoxic process.

The major challenge in development of siRNA therapeutics is delivery methods to the target cells in vivo. This is caused in part due to poor intracellular uptake and limited blood stability of siRNA. In order to achieve hepatocyte-targeted delivery of Fas siRNA and improved gene transfer by intravenous injection of a liposomes complex, some modifications were made to the original formulation to increase specifically targeting hepatocytes and encapsulation efficiency.

On the basis of previous reported that the galactose is a ligand that binds the asialoglycoprotein receptors (ASGP-R), which is specific for hepatocytes with a high affinity and a rapid internalization rate [23], galactosylated lipid was chemically synthesized through link galactose to the distal end of DSPE-PEG. DSPE-PEG is a PEGylated lipid, was prepared to keep the stabilization of the particles in a physiological condition and prolong the circulation time in vivo [23,28]. Cationic liposomes tend to aggregate in the presence of serum proteins and are taken up by the reticuloendothelial system due to their positive charge content [29]. To increase the serum stability of liposomes, the liposome surface was decorated with 10 mol % Gal-DSPE-PEG lipids by the post-insert method, which assures target ligand localization on the external surface of liposomes. Although some researchers reported ability to increase DSPE-PEG2000 concentration to 20 mol % to preventing aggregation induced by serum proteins [24], in our new liposome formulation, we found when increase DSPE-PEG2000 to 20 mol %, the zeta potential of liposomes become negative charged and reduce transfection efficiency is observed.

Protamine is a highly positive charged peptide that acts as nucleic acid condensation reagent. It reported that condensed siRNAs with protamine can increase delivery efficiency [30]. Apart from this, we found when lipid film was hydrated with a solution composed of protamine and condensed siRNA, it can achieves more than 90% entrapment efficacy compare with our previous report [31]. Correspondingly, the encapsulated siRNA was also sufficient for silencing Fas gene expression.

To develop efficacy and safety hepatocyte targeting siRNA delivery system, the side effect of immune activation with excessive cytokine release and associated inflammatory syndromes should be avoided. Therefore, we tested the levels of IFN-γ, TNF-α as well as IL-6 to investigate the toxicity of the Gal-LipoNP/siRNA complex. As shown in Figure 5, none of the Gal-LipoNP/siRNA complexes causes significant inflammatory syndromes and hepatitis in mice.

We employed two different delivery approaches to detect the gene silence efficiency. High-volume intravenous (hydrodynamic) injection of naked siRNA is currently the most common method for inducing RNAi in laboratory animals, despite the global gene-silencing effects and lack of feasibility for human application [32,33]. Although Song et al reported that the use of naked Fas siRNA through hydrodynamic injection can protect mice from fulminant hepatitis [9], this treatment required three times administration of Fas siRNA before ConA-induced hepatitis, which may limit therapeutic attractiveness. Water et al [34] investigated the behavior of naked siRNA distribution in vivo and reported that naked siRNA preferentially accumulates in the kidneys and is excreted in the urine. Santel et al [35] also reported the biodistribution peculiarity of naked Cy3 labeled siRNAs and discovered after 20 min post-injection, the naked siRNAs are predominantly found in the kidney, with no detectable signals in heart, liver, spleen, lung, and pancreas. Furthermore, they reported that naked siRNAs accumulates in the pole and lumen of the proximal tubules and in the urine 5 min after intravenous injection. These studies revealed that there is no selective uptake of siRNA to any cell type of the tissues investigated in vivo, and this is most likely due to instant renal excretion. Consistent with the current literature, we found that the majority of intravenously injected naked siRNA was concentrated in and cleared by the kidney soon after administration (Figure 2). If naked Fas siRNA was injected for one time and only less than 20% gene silence efficiency can be observed. In contrast, Gal-liposomes were primarily found in the liver at early time points and accumulated in liver until 48 h later can still see red fluorescence. Thus, our results suggest that Gal-liposomes mediated in vivo delivery may endow siRNA with a time-release property. Because siRNA is protected from endogenous nucleases within the liposomes interior and was targeted to hepatocytes through a specific ligands, it is possible that Gal-LipoNP accumulated in the hepatocytes-populated areas of the liver and slowly released their protected siRNA cargo, resulting in a prolonged gene-silencing effect.

In our study significant therapeutic effects were obtained in ConA induced hepatitis by specific silence Fas gene. Fas-mediated apoptosis play an important role in viral and autoimmune hepatitis, alcoholic liver disease [36]. The present study focuses on hepatocyte-targeted silencing of Fas gene. The use of Gal-LipoNP and hepatocyte-targeted delivery of siRNA is not only applicable for fulminant hepatitis but also for many other liver diseases such as transplant rejection, hypercholesterolemia, and hepatic genetic diseases. Similar strategy can be used to knock down other critical molecules associated with liver fibrosis, inflammation, as well as liver viral infections, such as hepatitis B virus [37] or hepatitis C virus [38].

In summary, our study demonstrates that siRNA could be specific delivered to the liver using galactosylated liposomes. The Gal-liposomes/siRNA complex can efficiently knock down Fas gene expression in liver; the results further clearly demonstrate that the application of Fas siRNA can prevent fulminant hepatitis. Consequently, the use of galactose ligated liposomes delivering siRNA may represent a promising clinical application of RNAi as a powerful tool for molecular therapy of many liver diseases.

**Acknowledgments**

We thank Weihua Liu for her technical assistance for histopathology experiments.
Author Contributions
Conceived and designed the experiments: NJ X. Zhang HW DQ VM GC WM. Performed the experiments: NJ X. Zhang Z. Zheng DC KS. Wrote the paper: NJ X. Zhang TI DQ GC WM.

References
1. Vaquero J, Blei AT (2003) Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 5: 39–47.
2. Sass DA, Shalik AO (2005) Fulminant hepatic failure. Liver Transpl 11: 594–605.
3. Agrawal N, Dasardhri PV, Mohmmed A, Malhotra P, Bhamaggar RK, et al. (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67: 657–659.
4. Kawakami S, Hashita M (2007) Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 22: 142–151.
5. Akhtar S, Benter I (2007) Toxigenicnemias of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59: 161–182.
6. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267: 9–21.
7. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG (1999) Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem 10: 289–298.
8. Scherr M, Battmer K, Dallmann I, Ganser A, Eder M (2003) Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 13: 353–363.
9. Song E, Lee SK, Wang J, Ince N, Ouyang N, et al. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 334–335.
10. Yano J, Hirabayashi K, Nakagawa S, Yamauchi T, Nogawa M, et al. (2004) Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 10: 7271–7276.
11. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, et al. (2006) RNA interference-mediated gene silencing of p53 expression by small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17: 751–766.
12. Ying RS, Zhu C, Fan XG, Li N, Tian XF, et al. (2007) Hepatit B virus is inhibited by RNA interference in cell culture and in mice. Antiviral Res 75: 24–30.
13. Moschos SA, Jones SW, Perry MM, Williams AE, Erefalt JS, et al. (2007) Lung delivery studies using siRNA conjugated to Tat/TAT(48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjugate Chem 18: 1450–1459.
14. Zender R, Huntke S, Liebholt C, Tillmann HH, Zender S, et al. (2003) Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 100: 7797–7802.
15. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, et al. (2004) Hydroperoxidase as the mechanism of hydrodynamic delivery. Gene Ther 11: 675–682.
16. Wu SY, McMillan NA (2009) Lipidic systems for in vivo siRNA delivery. AAPS J 11: 639–652.
17. Hughes J, Yadav P, Mesaros R (2010) Liposomal siRNA delivery. Methods Mol Biol 605: 445–459.
18. Rothdiener M, Muller D, Castro PG, Scholz A, Schwanenmuller M, et al. (2010) Targeted delivery of siRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release 144: 251–259.
19. Zhang X, Tian D, Wong A, Bygrave M, Ichim TE, et al. (2009) Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation 120: 1099–1107, 1091 p following 1107.
20. Gabizon A, Horovitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, et al. (1999) Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem 10: 289–298.
21. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, et al. (2000) Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 97: 5498–5503.
22. Liu X, Wang JM (2011) Iridoid glycosides fraction of Folinium syringae leaves modulates NF-kappaB signal pathway and intestinal epithelial cells apoptosis in experimental colitis. PLoS One 6: e24748.
23. Wang E (1999) Application of membrane-active peptides for nonviral gene delivery. Adv Drug Deliv Rev 38: 279–299.
24. Li SD, Huang L (2006) Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3: 579–588.
25. Galle PR, Hofmann WJ, Walczak H, Schaller O, Otto G, et al. (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223–1230.
26. Lacroix M, Vignon A, Fabre M, Vialot B, Rouquet N, et al. (1996) Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 2: 80–86.
27. Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides 19: 89–102.
28. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, et al. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88: 11650–11654.
29. Plank C, Tang MX, Wolfe AR, Sooka FC Jr. (1999) Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum Gene Ther 10: 319–332.
30. Sorgi FL, Bhattacharya S, Huang L (1997) Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 4: 961–968.
31. Zheng X, Vladuc C, Zhang X, Suzuki M, Ichim TE, et al. (2009) A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 113: 2646–2654.
32. Zhang G, Bodur S, Wolf JJ (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10: 1735–1737.
33. Wesh-Soldato DE, Chung CS, Lomas-Neira J, Doughly LA, Gregory SH, et al. (2005) In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 106: 2295–2301.
34. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Ruel SG, et al. (2006) Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34: 1393–1397.
35. Santel A, Alecu M, Kiel O, Erdruschat J, Esche V, et al. (2006) A novel siRNA-lipoxen technology for RNA interference in the mouse vascular endothelium. Gene Ther 13: 1222–1234.
36. Tagami A, Ohnishi H, Moriwaki H, Phillips M, Hughes RD (2003) Fomodulated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology 50: 1065–1071.
37. Rauschhuber C, Xu H, Salazar FH, Marion PL, Ehrhardt A (2008) Exploring siRNA delivery. Adv Drug Deliv Rev 60: 75–81.
38. Santel A, Alecu M, Kiel O, Erdruschat J, Esche V, et al. (2006) A novel siRNA-lipoxen technology for RNA interference in the mouse vascular endothelium. Gene Ther 13: 1222–1234.